Evidence map›Paper›PMID 38255871›Full record

ReviewInternational journal of molecular sciences2024

From Ocean to Medicine: Harnessing Seaweed's Potential for Drug Development.

João Cotas, Silvia Lomartire, Ana M M Gonçalves, Leonel Pereira

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Marine drugs · 2026
    Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

João CotasMarine Resources, Conservation and Technology, Marine Algae Lab, CFE-Centre for Functional Ecology: Science for People & Planet, Department of Life Sciences, University of Coimbra, 3000-456 Coimbra, Portugal.ORCID 0000-0002-5244-221X
Silvia LomartireMarine Resources, Conservation and Technology, Marine Algae Lab, CFE-Centre for Functional Ecology: Science for People & Planet, Department of Life Sciences, University of Coimbra, 3000-456 Coimbra, Portugal.
Ana M M GonçalvesMarine Resources, Conservation and Technology, Marine Algae Lab, CFE-Centre for Functional Ecology: Science for People & Planet, Department of Life Sciences, University of Coimbra, 3000-456 Coimbra, Portugal.ORCID 0000-0002-8611-7183
Leonel PereiraMarine Resources, Conservation and Technology, Marine Algae Lab, CFE-Centre for Functional Ecology: Science for People & Planet, Department of Life Sciences, University of Coimbra, 3000-456 Coimbra, Portugal.ORCID 0000-0002-6819-0619

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Seaweed, a miscellaneous group of marine algae, has long been recognized for its rich nutritional composition and bioactive compounds, being considered nutraceutical ingredient. This revision delves into the promising role of seaweed-derived nutrients as a beneficial resource for drug discovery and innovative product development. Seaweeds are abundant sources of essential vitamins, minerals, polysaccharides, polyphenols, and unique secondary metabolites, which reveal a wide range of biological activities. These bioactive compounds possess potential therapeutic properties, making them intriguing candidates for drug leads in various medical applications and pharmaceutical drug development. It explores their pharmacological properties, including antioxidant, anti-inflammatory, antimicrobial, and anticancer activities, shedding light on their potential as therapeutic agents. Moreover, the manuscript provides insights into the development of formulation strategies and delivery systems to enhance the bioavailability and stability of seaweed-derived compounds. The manuscript also discusses the challenges and opportunities associated with the integration of seaweed-based nutrients into the pharmaceutical and nutraceutical industries. Regulatory considerations, sustainability, and scalability of sustainable seaweed sourcing and cultivation methods are addressed, emphasizing the need for a holistic approach in harnessing seaweed's potential. This revision underscores the immense potential of seaweed-derived compounds as a valuable reservoir for drug leads and product development. By bridging the gap between marine biology, pharmacology, and product formulation, this research contributes to the critical advancement of sustainable and innovative solutions in the pharmaceutical and nutraceutical sectors.

Indexed as

MedicineDrug DevelopmentOceans and SeasPharmaceutical VehiclesVitaminsPharmaceutical VehiclesVitaminsbioactive compoundsdrug developmentdrug discoveryformulation strategiespharmacological activitiesseaweed-derived compounds

Identifiers

PMID38255871
PMCPMC10815561

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.